Implications of Neuroendocrine Tumor and Diabetes Mellitus on Patient Outcomes and Care: a Matched Case-control Study

Overview

Journal Future Sci OA

Specialty Biotechnology

Date 2021 May 28

PMID 34046189

Citations 4

Authors

Yael N Kusne

Heidi E Kosiorek

Matthew R Buras

Patricia M Verona

Kyle E Coppola

Kelley A Rone

Curtiss B Cook

Nina J Karlin

Affiliations

Soon will be listed here.

Abstract

Aim: We aimed to determine the impact of diabetes mellitus (DM) on survival of patients with neuroendocrine tumors (NETs) and of NETs on glycemic control.

Patients & Methods: Patients with newly diagnosed NETs with/without DM were matched 1:1 by age, sex and diagnosis year (2005-2017), and survival compared (Kaplan-Meier and Cox proportional hazards). Mixed models compared hemoglobin A (HbA) and glucose during the year after cancer diagnosis.

Results: Three-year overall survival was 72% (95% CI: 60-86%) for DM patients versus 80% (95% CI: 70-92%) for non-DM patients (p = 0.82). Hazard ratio was 1.33 (95% CI: 0.56-3.16; p = 0.51); mean DM HbA, 7.3%.

Conclusion: DM did not adversely affect survival of patients with NET. NET and its treatment did not affect glycemic control.

Citing Articles

Incidentally Found Rectal Carcinoid Tumor in a 46-Year-Old Female: The Potential for Complications and the Importance of Screening Guidelines.

Lapides R, Shah A, Bal S Cureus. 2024; 16(2):e55163.

PMID: 38558605 PMC: 10980541. DOI: 10.7759/cureus.55163.

Assessment of the Role of Leptin and Adiponectinas Biomarkers in Pancreatic Neuroendocrine Neoplasms.

Bocian-Jastrzebska A, Malczewska-Herman A, Rosiek V, Kos-Kudla B Cancers (Basel). 2023; 15(13).

PMID: 37444627 PMC: 10340778. DOI: 10.3390/cancers15133517.

Cancer, diabetes, survival and glycemic control: a large multisite analysis.

Karlin N, Kosiorek H, Verona P, Coppola K, Cook C Future Sci OA. 2023; 8(9):FSO820.

PMID: 36788982 PMC: 9912249. DOI: 10.2144/fsoa-2022-0018.

Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms.

Lan X, Fazio N, Abdel-Rahman O Metabolites. 2022; 12(11).

PMID: 36422290 PMC: 9693308. DOI: 10.3390/metabo12111150.

References

Tsilidis K, Kasimis J, Lopez D, Ntzani E, Ioannidis J . Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015; 350:g7607. DOI: 10.1136/bmj.g7607. View

Sandini M, Strobel O, Hank T, Lewosinska M, Niessen A, Hackert T . Pre-operative dysglycemia is associated with decreased survival in patients with pancreatic neuroendocrine neoplasms. Surgery. 2020; 167(3):575-580. DOI: 10.1016/j.surg.2019.11.007. View

Hassan M, Phan A, Li D, Dagohoy C, Leary C, Yao J . Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer. 2008; 123(4):867-73. DOI: 10.1002/ijc.23529. View

Karlin N, Amin S, Kosiorek H, Buras M, Verona P, Cook C . Survival and glycemic control outcomes among patients with coexisting pancreatic cancer and diabetes mellitus. Future Sci OA. 2018; 4(4):FSO291. PMC: 5905610. DOI: 10.4155/fsoa-2017-0144. View

Chung C . Management of neuroendocrine tumors. Am J Health Syst Pharm. 2016; 73(21):1729-1744. DOI: 10.2146/ajhp150373. View

Maggard M, OConnell J, Ko C . Updated population-based review of carcinoid tumors. Ann Surg. 2004; 240(1):117-22. PMC: 1356383. DOI: 10.1097/01.sla.0000129342.67174.67. View

Giovannucci E, Harlan D, Archer M, Bergenstal R, Gapstur S, Habel L . Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33(7):1674-85. PMC: 2890380. DOI: 10.2337/dc10-0666. View

Karlin N, Amin S, Buras M, Kosiorek H, Verona P, Cook C . Patient outcomes from lung cancer and diabetes mellitus: a matched case-control study. Future Sci OA. 2017; 4(1):FSO248. PMC: 5729608. DOI: 10.4155/fsoa-2017-0081. View

Pusceddu S, Buzzoni R, Vernieri C, Concas L, Marceglia S, Giacomelli L . Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. Future Oncol. 2016; 12(10):1251-60. DOI: 10.2217/fon-2015-0077. View

10.

Herrera-Martinez A, Pedraza-Arevalo S, L-Lopez F, Gahete M, Galvez-Moreno M, Castano J . Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?. J Clin Endocrinol Metab. 2018; 104(1):57-73. DOI: 10.1210/jc.2018-01455. View

11.

Wermers R, Fatourechi V, Wynne A, Kvols L, Lloyd R . The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996; 75(2):53-63. DOI: 10.1097/00005792-199603000-00002. View

12.

Armstrong E, Beal E, Lopez-Aguiar A, Poultsides G, Cannon J, Rocha F . Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. Am Surg. 2020; 85(12):1334-1340. PMC: 10188290. View

13.

Pape U, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M . Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008; 15(4):1083-97. DOI: 10.1677/ERC-08-0017. View

14.

Karlin N, Amin S, Verona P, Kosiorek H, Cook C . CO-EXISTING PROSTATE CANCER AND DIABETES MELLITUS: IMPLICATIONS FOR PATIENT OUTCOMES AND CARE. Endocr Pract. 2017; 23(7):816-821. DOI: 10.4158/EP161702.OR. View

15.

Gallo M, Ruggeri R, Muscogiuri G, Pizza G, Faggiano A, Colao A . Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?. Cancer Treat Rev. 2018; 67:1-9. DOI: 10.1016/j.ctrv.2018.04.013. View

16.

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y . Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017; 3(10):1335-1342. PMC: 5824320. DOI: 10.1001/jamaoncol.2017.0589. View

17.

Ben Q, Zhong J, Fei J, Chen H, Yv L, Tan J . Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study. Sci Rep. 2016; 6:36073. PMC: 5080551. DOI: 10.1038/srep36073. View

18.

Turaga K, Kvols L . Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2011; 61(2):113-32. DOI: 10.3322/caac.20097. View

19.

Barone B, Yeh H, Snyder C, Peairs K, Stein K, Derr R . Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008; 300(23):2754-64. PMC: 3093051. DOI: 10.1001/jama.2008.824. View

20.

Modlin I, Lye K, Kidd M . A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97(4):934-59. DOI: 10.1002/cncr.11105. View